amoxicillin-potassium-clavulanate-combination and marbofloxacin

One hundred and four dogs with clinical signs of urinary tract infection were selected by 15 practitioners in a multicentric, controlled and randomised study. The clinical diagnosis was confirmed by urinalysis and imaging. Each dog received either marbofloxacin (2 mg/kg orally once daily or 4 mg/kg by subcutaneous injection every four days) or amoxicillin-clavulanic acid tablets (12.5 mg/kg twice daily) for 10 or 28 days, depending on the clinical diagnosis. Rectal temperature, general condition, appetite, urinary signs, defecation disorders and pain on abdominal palpation were monitored at each visit, the timetable depending on diagnosis: three urinalyses and at least three examinations per case were performed. Side effects were also thoroughly sought at each examination. Marbofloxacin and amoxicillin-clavulanic acid both yielded good bacteriological cure rates (96.2 per cent versus 85.0 per cent, respectively) and clinical cure rates (83.3 per cent versus 69.7 per cent). Fewer relapses were observed in those dogs that received marbofloxacin. Few mild side effects were recorded with both products.

Topics: Administration, Oral; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Infective Agents; Bacteria; Clavulanic Acids; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Fluoroquinolones; Injections, Subcutaneous; Male; Quinolones; Recurrence; Treatment Outcome; Urinary Tract Infections

Feline lung worm infection is increasingly reported in recent years, and recognized as a cause for respiratory disease in cats. Aelurostrongylus abstrusus is regarded as the most prevalent cause of such cases. Infective L3 larvae carried in gastropods and paratenic hosts infect felines, developing to adult worms that reside in the lungs' parenchyma and may cause verminous pneumonia. The L1 larvae hatch from eggs deposited in the lung, and are released to the environment by either feces or sputum. While the majority of epidemiological information regarding A. abstrusus originates in European countries, recent studies have shown that it is also found around the Mediterranean basin, as far east as Turkey and Cyprus. A local domestic cat from Israel showing signs of respiratory illness was diagnosed with aelurostrongylosis, confirmed by both morphological and molecular tools. Presence in Israel of this nematode was previously reported in 1949, with no further mentions since. ITS-2 sequence of the isolated larvae was highly similar to that of A. abstrusus from domestic cats from Italy. These findings show that distribution of A. abstrusus stretch to the eastern shores of the Mediterranean, and that this nematode should be considered as a cause for respiratory disease in cats in Israel and the surrounding countries.

Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Antinematodal Agents; Bayes Theorem; Bronchoalveolar Lavage Fluid; Cat Diseases; Cats; DNA, Helminth; Feces; Fenbendazole; Fluoroquinolones; Israel; Larva; Lung; Male; Metastrongyloidea; Phylogeny; Polymerase Chain Reaction; Prednisolone; Radiography, Thoracic; Strongylida Infections

One hundred and three cats presenting with clinical signs of feline acute upper respiratory infection were selected from Belgium, France and the Netherlands in a randomised comparative field trial. Each cat underwent a bacteriological examination before treatment (day 0) and received either marbofloxacin, at a dosage of 2 mg/kg once daily for five days, or amoxycillin-clavulanic acid (ACA) at a dosage of 12.5 mg/kg twice daily for five days. Clinical examinations were performed on days 2, 5 and 14. Pasteurella species were cultured in one-third of the samples. The other main bacteria isolated were Streptococcaceae, Enterobacteriaceae and Staphylococcaceae. Response rates (cures + improvements) to treatment on day 5 were 87.8 vs 77.8 per cent for marbofloxacin and ACA, respectively. A few mild side-effects (diarrhoea, vomiting) were recorded with both drugs.

Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Infective Agents; Cat Diseases; Cats; Fluoroquinolones; Quinolones; Random Allocation; Respiratory Tract Infections; Treatment Outcome